Table 4.

Unsuccessful local tumor control after SRFA

Patient	Age	Sex	Tumor	Cirr.	Tumor size	N needles	Ablation time	Unsuccessful Pretherapy	Outcome
1	65	Male	HCC	Yes	7.0 cm	5	32 min	No	LR
2	74	Male	HCC	No	7.0 cm	8	72 min	No	LR
3	75	Male	ICC	No	6.0 cm	5	34 min	No	LR
4	54	Male	CRC	No	10.0 cm	10	112 min	No	LR
5	38	Male	CRC	No	1.0 cm	1	12 min	SRFA	LR
6	57	Male	HCC	Yes	2.6 cm	3	16 min	No	LR
7	69	Male	HCC	Yes	2.0 cm	3	16 min	No	LR
8	69	Male	HCC	Yes	1.0 cm	1	12 min	No	LR
8	69	Male	HCC	Yes	1.0 cm	1	12 min	SRFA	LR
9	60	Male	HCC	Yes	2.8 cm	3	16 min	No	LR
10	66	Female	HCC	Yes	4.5 cm	8	66 min	No	LR
11	48	Male	HCC	No	6.4 cm	12	128 min	No	LR
11	48	Male	HCC	No	5.0 cm	9	64 min	SRFA	LR
12	69	Male	HCC	Yes	5.0 cm	9	96 min	TACE	LR
13	61	Male	CRC	No	4.0 cm	5	29 min	No	LR
13	61	Male	CRC	No	2.5 cm	5	26 min	SRFA	LR
14	68	Male	MEL	No	5.5 cm	8	36 min	No	LR
15	73	Male	HCC	Yes	5.0 cm	9	39 min	No	LR
16	47	Male	NET	No	3.5 cm	3	32 min	No	LR
16	47	Male	NET	No	2.0 cm	2	24 min	No	LR
17	55	Female	OVC	No	2.5 cm	4	32 min	No	LR
18	68	Male	RCC	No	1.0 cm	3	12 min	No	IN
19	65	Male	HCC	Yes	1.3 cm	2	12 min	No	IN
20	49	Male	CRC	No	2.3 cm	2	12 min	No	IN
5	38	Male	CRC	No	2.0 cm	1	12 min	No	IN
21	58	Male	CRC	No	7.0 cm	9	66 min	No	IN
21	58	Male	CRC	No	5.0 cm	7	52 min	No	IN

SRFA stereotactic radiofrequency ablation, HCC hepatocellular carcinoma, CRC colorectal carcinoma, ICC intrahepatic cholangiocarcinoma, MEL melanoma, NET neuroendocrine tumor, OVC ovarian cancer, RCC renal cell cancer, Cirr. hepatic cirrhosis, IN incomplete necrosis, LR local recurrence, TACE transcatheter arterial chemoembolization